9 Results for "

immune checkpoint blockade

" in MedChemExpress (MCE) Product Catalog:
Products (9)

9 Results for "immune checkpoint blockade" in MCE Product Catalog:

4
4 Cited Publications
Cat. No.: HY-156677
CAS No.: 2648257-56-9
Purity:  99.90%
Target:  

METTL3

Research Areas:  

Cancer

STC-15 is an orally active RNA methyltransferase METTL3 inhibitor with the activity of activating anti-tumor immunity and reshaping the tumor microenvironment. STC-15 inhibits tumor growth by activating anti-cancer immune responses associated with increased interferon signaling and synergizes with T-cell checkpoint blockade. STC-15 can be used in the study of proliferative diseases such as cancer and autoimmune diseases .
loading...
    loading...
Cat. No.: HY-P99540
CAS No.: 2417649-44-4
Synonyms: PSB-205; QL1706 (iparomlimab/tuvonralimab); PBS105

Target:  

CTLA-4

Research Areas:  

Cancer

Tuvonralimab (PSB-205) is a humanized IgG1 monoclonal antibody against CTLA-4. Tuvonralimab can be used in the research of tumors. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
loading...
    loading...
Cat. No.: HY-144501
CAS No.: 2230218-36-5
Purity:  98.14%
D18 is an immune modulator. D18 acts as a TLR7/8 dual agonist (EC50 = 24 nM for hTLR7 and 10 nM for hTLR8, respectively). D18 increases PD-L1 expression through epigenetic regulation, thus sensitizing tumors to PD-1/PD-L1 blockade. D18 is a ADC cytotoxin uesd for the systhesis of ADC HE-S2 (HY-144497). D18 has strong immune activation and anti-tumor activity. D18 commonly used in cancer research, such as colon cancer .
loading...
    loading...
Cat. No.: HY-169232
Target:  

PROTACs PD-1/PD-L1

Research Areas:  

Cancer

PCC16 chloride is a dual PROTAC degrader targeting DHHC3 and PD-L1, with a DC50 of 0.103 μM for PD-L1 degradation. PCC16 chloride induces DHHC3 degradation via the ubiquitin-proteasome pathway by recruiting the CRBN E3 ubiquitin ligase (E3 ubiquitin ligase). By targeting DHHC3-which is essential for PD-L1 palmitoylation and membrane stability-PCC16 chloride reduces PD-L1 levels, decreases PD-L1 membrane retention time, and impairs its immunosuppressive function. PCC16 chloride enhances anti-tumor immunity by disrupting PD-L1-mediated immunosuppression. PCC16 chloride can be used in the research of immune checkpoint blockade-resistant cancers .
loading...
    loading...
Cat. No.: HY-163844
Target:  

PD-1/PD-L1

Research Areas:  

Inflammation/Immunology Cancer

PD-1/PD-L1-IN-49 (compound 1c) is a potent inhibitor of PD-1/PD-L1, with the IC50 of 77 nM. PD-1/PD-L1-IN-49 activates Jurkat T cells, reflecting successful blockade of the PD-1/PD-L1 immune checkpoint .
loading...
    loading...
Cat. No.: HY-P11061
CAS No.: 2036056-69-4
Target:  

Peptides

Research Areas:  

Cancer

M27 peptide is an MHC class I epitope antigen that can be used in cancer nanovaccine research .
loading...
    loading...
Cat. No.: HY-P11062
CAS No.: 1415031-10-5
Synonyms: MUT30
Target:  

Peptides

Research Areas:  

Cancer

M30 peptide is an MHC class II epitope antigen that can be used in cancer nanovaccine research .
loading...
    loading...
Cat. No.: HY-184203
Target:  

HDAC

Research Areas:  

Cancer

SM-06-09 is a potent, highly selective, orally active tetrazolone-based HDAC6 inhibitor with an IC50 value of 0.49 nM. SM-06-09 promotes tumor-associated macrophage (TAM) polarization toward an antitumor M1-like phenotype and enhances macrophage phagocytosis, antigen presentation, and T-cell activation. SM-06-09 remodels the tumor immune microenvironment, exhibits antitumor activity in melanoma models, and enhances the efficacy of anti-PD-1 immune checkpoint blockade .
loading...
    loading...
Cat. No.: HY-184119
CAS No.: 3061276-55-6
Synonyms: IM502
Pabgraminone C (IM502) is a Fungal metabolite and PI3Kγ inhibitor with an IC50 of 61.7 nM against PI3Kγ. Pabgraminone C shifts the STAT signaling pathway in cells from an immunosuppressive STAT3/STAT6-dominant profile to an immunostimulatory STAT1/STAT2-dominant profile, driving cells toward a pro-inflammatory phenotype. Pabgraminone C reprograms cells from an immunosuppressive state to an immunostimulatory state, reversing their suppressive effect on anti-tumor immunity. Pabgraminone C inhibits established tumor growth and metastasis across multiple cancer types. Pabgraminone C overcomes resistance to PD-1 checkpoint blockade strategies. Pabgraminone C can be used in research related to liver cancer, melanoma, and colorectal cancer .
loading...
    loading...